Literature DB >> 3762619

Relation of glucose tolerance to complications of pregnancy in nondiabetic women.

L Tallarigo, O Giampietro, G Penno, R Miccoli, G Gregori, R Navalesi.   

Abstract

An increase in fetal and maternal complications has been documented in cases of gestational diabetes, but the glucose levels that predict an increased risk have not been clearly defined. We evaluated the frequency of several neonatal complications (macrosomia, congenital anomalies, perinatal mortality, and prematurity) and maternal complications (toxemia, cesarean section, or both) in relation to glucose tolerance in 249 women in the third trimester of pregnancy. None of the women had previous evidence of diabetes, and all had normal results on an oral glucose-tolerance test, according to accepted criteria. On the basis of their two-hour plasma glucose levels, women were divided into three groups: A (glucose less than 100 mg per deciliter), B (glucose 100 to 119 mg per deciliter), and C (glucose 120 to 164 mg per deciliter). The higher two-hour plasma glucose levels were associated with a significant increase in the incidence of macrosomia (9.9, 15.5, and 27.5 percent in Groups A, B, and C, respectively), congenital abnormalities (0.7, 3.5, and 5.0 percent), and toxemia, cesarean section, or both (19.9, 25.9, and 40.0 percent). A significant correlation between the infant's weight and the mother's two-hour plasma glucose level was also observed. These data indicate that even limited degrees of maternal hyperglycemia, which are currently considered to be within the normal range, may affect the outcome of pregnancy.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3762619     DOI: 10.1056/NEJM198610163151603

Source DB:  PubMed          Journal:  N Engl J Med        ISSN: 0028-4793            Impact factor:   91.245


  34 in total

1.  Normoblasts in large for gestational age infants.

Authors:  S Dollberg; R Marom; F B Mimouni; M Yeruchimovich
Journal:  Arch Dis Child Fetal Neonatal Ed       Date:  2000-09       Impact factor: 5.747

Review 2.  Glycemic targets in pregnancies affected by diabetes: historical perspective and future directions.

Authors:  Teri L Hernandez
Journal:  Curr Diab Rep       Date:  2015-01       Impact factor: 4.810

Review 3.  Maternal factors that determine neonatal size and body fat.

Authors:  P M Catalano; J P Kirwan
Journal:  Curr Diab Rep       Date:  2001-08       Impact factor: 4.810

Review 4.  Periodic health examination, 1992 update: 1. Screening for gestational diabetes mellitus. Canadian Task Force on the Periodic Health Examination.

Authors: 
Journal:  CMAJ       Date:  1992-08-15       Impact factor: 8.262

5.  Differential regulation of genes for fetoplacental lipid pathways in pregnancy with gestational and type 1 diabetes mellitus.

Authors:  Tatiana Radaelli; Jacques Lepercq; Ali Varastehpour; Subhabrata Basu; Patrick M Catalano; Sylvie Hauguel-De Mouzon
Journal:  Am J Obstet Gynecol       Date:  2009-06-26       Impact factor: 8.661

6.  Associations of physical activity and inactivity before and during pregnancy with glucose tolerance.

Authors:  Emily Oken; Yi Ning; Sheryl L Rifas-Shiman; Jenny S Radesky; Janet W Rich-Edwards; Matthew W Gillman
Journal:  Obstet Gynecol       Date:  2006-11       Impact factor: 7.661

7.  Relation of birthweight to maternal plasma glucose and insulin concentrations during normal pregnancy.

Authors:  M C Breschi; G Seghieri; G Bartolomei; A Gironi; S Baldi; E Ferrannini
Journal:  Diabetologia       Date:  1993-12       Impact factor: 10.122

Review 8.  Clinical practice guidelines for treatment of diabetes mellitus. Expert Committee of the Canadian Diabetes Advisory Board.

Authors: 
Journal:  CMAJ       Date:  1992-09-01       Impact factor: 8.262

9.  Counterpoint: Selective screening for gestational diabetes mellitus.

Authors:  Howard Berger; Mathew Sermer
Journal:  Diabetes Care       Date:  2009-07       Impact factor: 17.152

10.  Maternal glycemia and risk of large-for-gestational-age babies in a population-based screening.

Authors:  Zsuzsa Kerényi; Gyula Tamás; Mika Kivimäki; Andrea Péterfalvi; Eszter Madarász; Zsolt Bosnyák; Adam G Tabák
Journal:  Diabetes Care       Date:  2009-09-03       Impact factor: 17.152

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.